<DOC>
	<DOCNO>NCT00707070</DOCNO>
	<brief_summary>It phase IV multicentric , placebo-controlled , clinical trial investigate efficacy safety acitretin combine efalizumab therapy chronic plaque psoriasis . PASI 75 week 24 primary end point . PASI 75 week 12 , PASI 50 week 24 secondary end point . Safety measure monitor serum parameter include AST ; ALT ; gammaGT ; creatinine ; cholesterol triglyceride .</brief_summary>
	<brief_title>Combining Acitretin Efalizumab Therapy Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Men age 1870 Women postmenopausal Moderate severe chronic plaque psoriasis patient contraindication , intolerance non responsive cyclosporine , methotrexate PUVA PASI &gt; 10 e/o BSA ( Body Surface Area ) &gt; 10 Drug induce psoriasis Pustular erythrodermic psoriasis Fertile woman Pregnancy lactation cholesterol &gt; 230mg/dL e triglyceride &gt; 200 mg/dL Known intolerance efalizumab acitretin Serious infection enrollement History previous neoplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>acitretin</keyword>
	<keyword>efalizumab</keyword>
</DOC>